Atypical hemolytic-uremic syndrome
MONDO:0016244A rare, genetic thrombotic microangiopathy due to dysregulation of the alternative complement pathway and characterized by the triad of hemolytic anemia, thrombocytopenia, and acute renal dysfunction.
Also known as: Atypical Hemolytic Uremic Syndrome, D-HUS, aHUS, atypical HUS, atypical hemolytic uremic syndrome, hemolytic-uremic syndrome without diarrhea, hemolytic-uremic syndrome without diarrhoea, non-diarrhea-associated hemolytic uremic syndrome
65 clinical trials for this condition and its sub-types, 19 tagged with Atypical hemolytic-uremic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Atypical hemolytic-uremic syndrome
-
5 sub-types
- Atypical hemolytic-uremic syndrome with B factor anomaly 0 trials
- Atypical hemolytic-uremic syndrome with C3 anomaly 0 trials
- Atypical hemolytic-uremic syndrome with I factor anomaly 0 trials
- Atypical hemolytic-uremic syndrome with MCP/CD46 anomaly 0 trials
- Atypical hemolytic-uremic syndrome with thrombomodulin anomaly 0 trials
-
Can aHUS patients safely stop eculizumab? algorithm put to the test
Disease control CompletedAtypical hemolytic uremic syndrome (aHUS) is a rare disease that damages the kidneys by causing blood clots in small vessels. The drug eculizumab blocks the complement system and has greatly reduced kidney failure, but doctors do not know how long patients should stay on it. This…
Phase 4 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill shows promise for rare blood disorder aHUS
Disease control CompletedThis study tested a new oral medication called iptacopan in 34 adults with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots, low platelets, and kidney damage. The goal was to see if the drug could improve blood counts and kidney function w…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for rare kidney disease: eculizumab trial shows promise in china
Disease control CompletedThis study tested the drug eculizumab in 25 children and adults in China with a rare kidney condition called atypical hemolytic uremic syndrome (aHUS). The goal was to see if the drug could stop blood clots and improve kidney function. All participants received eculizumab intrave…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Egyptian hospitals uncover the hidden toll of a rare kidney disease
Knowledge-focused CompletedThis study reviews medical records of 200 people diagnosed with a rare blood and kidney disease called aHUS in Egyptian hospitals. Researchers want to learn about patient symptoms, treatments, and long-term health to help doctors diagnose and manage the disease better. No new tre…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC